APA

Friebe A., Schwarz M. J., Schmid-Wendtner M., Volkenandt M., Schmidt F., Horn M., Janssen G. & Schaefer M. (20070621). Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma. : Journal of immunotherapy (Hagerstown, Md. : 1997).

Chicago

Friebe Astrid, Schwarz Markus J, Schmid-Wendtner Monika, Volkenandt Matthias, Schmidt Folkhart, Horn Martin, Janssen Gesa and Schaefer Martin. 20070621. Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma. : Journal of immunotherapy (Hagerstown, Md. : 1997).

Harvard

Friebe A., Schwarz M. J., Schmid-Wendtner M., Volkenandt M., Schmidt F., Horn M., Janssen G. and Schaefer M. (20070621). Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma. : Journal of immunotherapy (Hagerstown, Md. : 1997).

MLA

Friebe Astrid, Schwarz Markus J, Schmid-Wendtner Monika, Volkenandt Matthias, Schmidt Folkhart, Horn Martin, Janssen Gesa and Schaefer Martin. Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma. : Journal of immunotherapy (Hagerstown, Md. : 1997). 20070621.